Last Chance to Save on a One-Day
Interactive Workshop with Special Emphasis on Rare Diseases
Clinical Trial Endpoints: Methods and Practice in
Developing Measurements
October 25
University of California | Washington, DC
October 25
University of California | Washington, DC
This one-day interactive workshop with special emphasis on rare
diseases will provide a detailed examination of the process for developing,
validating, and implementing patient-focused clinical trial outcome measures
that will meet regulatory requirements for adequate and well-controlled
clinical trials, product approval, and labeling.
Session Topics:
• Attention to Measurement in Clinical Trials: Why it Matters
• Preparing the Groundwork for Clinically Meaningful Measurement: Getting the Content Right
• Generating an Instrument with an Interpretable Score
• Incorporating a Well-Defined and Reliable Measure into and Adequate and Well-Controlled Study
• Attention to Measurement in Clinical Trials: Why it Matters
• Preparing the Groundwork for Clinically Meaningful Measurement: Getting the Content Right
• Generating an Instrument with an Interpretable Score
• Incorporating a Well-Defined and Reliable Measure into and Adequate and Well-Controlled Study
Patients and Patient Organizations are
invited to attend the conference, at a reduced registration fee of $400, to
network with other stakeholders in the Rare Diseases Community. Submit a registration form by fax to
+1.215.442.6199.
Related Events:
US Conference on Rare Diseases & Orphan Products:
Shaping the Future NowOctober 22-24 | Washington, DC
Co-sponsored by NORD
DIA Adaptive Designs in Clinical Trials: Overcoming Persistent Barriers
November 29-30 | Washington, DC
Data Monitoring Committees: Best Practices and Future Directions
November 29-30 | Washington, DC
November 29-30 | Washington, DC
Featured Media Partner for DIA/NORD’s US Conference on Rare Diseases & Orphan
Products:
BioCentury Publications, Inc. is recognized as the leading
provider of value-added information, analysis and data essential to the
development and sustainability of life science ventures.
www.biocentury.com
No comments:
Post a Comment